share_log

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga Real-time News ·  Dec 31, 2022 05:36

Gainers

  • Invacare (NYSE:IVC) stock rose 14.3% to $0.48 during Friday's after-market session. The market value of their outstanding shares is at $18.1 million.
  • Benitec Biopharma (NASDAQ:BNTC) stock increased by 11.7% to $0.19. The market value of their outstanding shares is at $5.3 million.
  • AlerisLife (NASDAQ:ALR) stock moved upwards by 9.09% to $0.6. The company's market cap stands at $19.5 million.
  • Renalytix (NASDAQ:RNLX) shares rose 8.55% to $2.03. The company's market cap stands at $76.0 million.
  • electroCore (NASDAQ:ECOR) shares increased by 8.52% to $0.28. The market value of their outstanding shares is at $19.8 million.
  • Statera BioPharma (NASDAQ:STAB) stock increased by 8.37% to $0.09. The company's market cap stands at $4.8 million.

Losers

  • Salarius Pharmaceuticals (NASDAQ:SLRX) shares declined by 13.7% to $1.32 during Friday's after-market session. The company's market cap stands at $3.0 million.
  • GreenLight Biosciences (NASDAQ:GRNA) stock declined by 10.17% to $1.06. The company's market cap stands at $160.6 million.
  • Intelligent Bio Solutions (NASDAQ:INBS) stock decreased by 8.91% to $0.18. The market value of their outstanding shares is at $3.3 million.
  • Baudax Bio (NASDAQ:BXRX) stock declined by 8.5% to $2.91. Trading volume for this security closed at 518.1K, accounting for 46.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.6 million.
  • Finch Therapeutics Group (NASDAQ:FNCH) shares decreased by 8.32% to $0.44. The market value of their outstanding shares is at $21.0 million.
  • Adaptimmune Therapeutics (NASDAQ:ADAP) stock declined by 7.54% to $1.35. The company's market cap stands at $221.1 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment